IPO filing research

Parabilis Medicines, Inc.

Pharmaceutical Preparations · PBLS

ipo filed Nasdaq Global Market S-1

Parabilis Medicines, Inc. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-05-19. Current deal snapshot: exchange Nasdaq Global Market.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS in the pre-IPO sequence.

Voting · Exchange Nasdaq Global Market · Ticker PBLS · Use of proceeds General corporate purposes · Underwriters Leerink Partners, BofA Securities, Evercore ISI

Parabilis Medicines, Inc. is advancing novel therapeutics targeting cancer driver targets with unique mechanisms, but faces significant risks in development, regulatory approval, and commercialization. The company highlights challenges in preclinical and clinical trials, reliance on third-party partners, financial constraints, and uncertainties in achieving development milestones. Its S-1 filing underscores the high-risk, high-reward nature of its pipeline, including zolucatetide for desmoid tumors, while emphasizing the potential for delays, increased costs, and regulatory hurdles.

2026-05-19 · 0001193125-26-230994

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

2026-04-02 · 0001193125-26-140488

Comparable Deals

14 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 14 using nearest neighbors.

Showing top 8 by similarity.

-0.3%

Median day-1

50%

Above issue

-3.0%

Median week-1

-20.9%

Downside (p10)

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SICrecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SICrecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SICrecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SICrecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SICrecent IPO

Aardvark Therapeutics, Inc. AARD

2026-02-06 $94M Day 1: -20.9% Wk 1: -23.3%

same SICrecent IPO

Odyssey Therapeutics, Inc. ODTX

2026-05-08 $279M Day 1: -8.8% Wk 1: -3.8%

same SIC grouprecent IPO

Hemab Therapeutics Holdings, Inc. COAG

2026-05-01 $302M Day 1: +88.9% Wk 1: +43.0%

same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.